Tuberculosis and Respiratory Diseases

The Korean Academy of Tuberculosis and Respiratory Diseases (대한결핵및호흡기학회)
권호 표지

Comparison of Effect Between Thrombolysis and Anticoagulation in Major Pulmonary Thromboembolism

쇽 혹은 우심실부전을 보이는 중증 폐혈전색전증에서 혈전용해요법과 항응고요법의 효과

  • Han, Song Yi (Divisions of Pulmonary, University of Ulsan College of Medicine, Asan Medical Center) ;
  • Song, Jae Kwan (Divisions of Cardiology, University of Ulsan College of Medicine, Asan Medical Center) ;
  • Lee, Sang Do (Divisions of Pulmonary, University of Ulsan College of Medicine, Asan Medical Center) ;
  • Lim, Chae-Man (Divisions of Pulmonary, University of Ulsan College of Medicine, Asan Medical Center) ;
  • Koh, Younsuck (Divisions of Pulmonary, University of Ulsan College of Medicine, Asan Medical Center) ;
  • Park, Chan Sun (Divisions of Pulmonary, University of Ulsan College of Medicine, Asan Medical Center) ;
  • Oh, Yeon Mok (Divisions of Pulmonary, University of Ulsan College of Medicine, Asan Medical Center) ;
  • Shim, Tae Sun (Divisions of Pulmonary, University of Ulsan College of Medicine, Asan Medical Center) ;
  • Kim, Woo Sung (Divisions of Pulmonary, University of Ulsan College of Medicine, Asan Medical Center) ;
  • Kim, Dong Soon (Divisions of Pulmonary, University of Ulsan College of Medicine, Asan Medical Center) ;
  • Kim, Won Dong (Divisions of Pulmonary, University of Ulsan College of Medicine, Asan Medical Center) ;
  • Hong, Sang-Bum (Divisions of Pulmonary, University of Ulsan College of Medicine, Asan Medical Center)
  • 한송이 (울산대학교 의과대학 서울아산병원 호흡기내과) ;
  • 송재관 (울산대학교 의과대학 서울아산병원 심장내과) ;
  • 이상도 (울산대학교 의과대학 서울아산병원 호흡기내과) ;
  • 임채만 (울산대학교 의과대학 서울아산병원 호흡기내과) ;
  • 고윤석 (울산대학교 의과대학 서울아산병원 호흡기내과) ;
  • 박찬선 (울산대학교 의과대학 서울아산병원 호흡기내과) ;
  • 오연목 (울산대학교 의과대학 서울아산병원 호흡기내과) ;
  • 심태선 (울산대학교 의과대학 서울아산병원 호흡기내과) ;
  • 김우성 (울산대학교 의과대학 서울아산병원 호흡기내과) ;
  • 김동순 (울산대학교 의과대학 서울아산병원 호흡기내과) ;
  • 김원동 (울산대학교 의과대학 서울아산병원 호흡기내과) ;
  • 홍상범 (울산대학교 의과대학 서울아산병원 호흡기내과)
  • Received : 2005.07.22
  • Accepted : 2005.09.14
  • Published : 2005.11.30
Download PDF
⟨ Previous Next ⟩

Abstract

Background : 'Major pulmonary thromboembolism' is defined as right ventricular (RV) dysfunction, with or without shock, accompanied by significant morbidity and mortality. In this study, those with major pulmonary thromboembolism were divided into the shock and RV dysfunction only groups, and then investigated the mortality and complications in thrombolysis or anticoagulation, respectively. Methods : In a retrospective study, between January 1995 and December 2004, 60 eligible patients with a major pulmonary thromboembolism, admitted in Asan Medical Center, were included. Results : A total of 57 patients were treated with medical therapy. Thrombolysis was performed in 13 patients (23%) and anticoagulation in 44 (77%). There were no differences in the APACHEII and SOFA scores between the two groups. 6 (46%) and 11 (25%) patients died in the thrombolysis and anticoagulation groups, respectively (p=0.176). In the 19 patients (33%) showing shock, thrombolysis was performed in 9 (47%) and anticoagulation in 10 (53%). 4 (44%) of the 9 patients treated with thrombolytic agents and 3 (30%) of the 10 treated with anticoagulants died (p=0.650). In the 38 patients (67%) showing RV dysfunction only, thrombolysis was performed in 4 (11%) and anticoagulation in 34 (89%). 2 (50%) of the 4 patients treated with thrombolytics and 8 (24%) of the 34 treated with anticoagulants died (p=0.279). Three patients (23%) who underwent thrombolysis had a major bleeding episode, compared with 2 (5%) who were treated with anticoagulants (p=0.072). Conclusion: The results of our study showed that thrombolysis did not lower mortality and tended to increase major bleeding compared with anticoagulation in both the shock and RV dysfunction only groups. Further evaluation of the efficacy and safety of thrombolytic therapy for major thromboembolism appears warranted in Korea.

연구배경 : 우심실부전 또는 쇽을 보였던 중증 폐색전증에서 혈전용해요법 혹은 항응고요법을 시행했을 때 예후의 차이에 대해 조사해 보고자 하였다. 방 법 : 1995년 1월부터 2004년 12월까지 서울아산병원에 입원했던 폐색전증 환자 중에서 우심실부전 혹은 쇽이 있었던 총 60명의 환자를 대상으로 의무기록 분석을 통해서 후향적으로 조사하였다. 결 과 : 총 57명의 환자가 혈전용해요법 또는 항응고요법을 시행 받았으며, 이 중 혈전용해제는 13명(23%)에서, 항응고제는 44명(77%)에서 사용되었다. 혈전용해요법 군과 항응고요법 군에서 APACHEII 점수나 SOFA 점수에 차이는 없었고 사망률은 각각 46% (6/13), 16% (7/44)였다(p=0.054). 쇽이 있는 19명(33%)의 환자 중 혈전용해요법은 9명(47%), 항응고요법은 10명(53%)에서 시행되었고 사망률은 각각 44% (4/9), 30% (3/10)로 차이가 없었다(p=0.650). 38명(67%)의 우심실부전 군에서 혈전용해요법은 4명(11%), 항응고요법은 34명(89%)에서 시행되었고 사망률은 50% (2/4), 24% (8/34)로 차이가 없었다(p=0.279). 중요 출혈부작용은 혈전용해요법 군과 항응고요법 군에서 23% (3/13), 5% (2/44)로 혈전용해요법이 높은 경향을 보였다(p=0.072). 결 론 : 중증 폐혈전색전증 환자에서 쇽 군과 우심실부전군을 각각 혈전용해요법과 항응고요법으로 치료했을 때, 두 군 모두에서 혈전용해요법이 항응고요법에 비해 사망률을 감소시키지 못했으며, 출혈부작용은 높은 경향을 보였다. 그러므로 우리나라에서 전향적 대규모 연구가 필요할 것으로 사료된다.

Keywords

References

  1. Anderson FA Jr, Wheeler HB, Goldberg RJ, Hosmer DW, Patwardhan NA, Jovanovic B, et al. A population-based perspective of the hospital incidence and case-fatality rates of deep-vein thrombosis and pulmonary embolism: the Worcester DVT study. Arch Intern Med 1991;151:933-8 https://doi.org/10.1001/archinte.151.5.933
  2. Goldhaber SZ, Visani L, de Rosa M. Acute pulmonary embolism: clinical outcomes in the International Cooperative Pulmonary Embolism Registry (ICOPER). Lancet 1999;353:1386-9 https://doi.org/10.1016/S0140-6736(98)07534-5
  3. Scientific Committee for National Survey of Acute Pulmonary Thromboembolism, Korea Academy of Tuberculosis and Respiratory Disease. The National survey of acute pulmonary thromboembolism in Korea. Tuberc Respir Dis 2003;54:5-14 https://doi.org/10.4046/trd.2003.54.1.5
  4. Konstantinides S, Geibel A, Kasper W. Predictors of in-hospital mortality in patients with acute massive pulmonary embolism: results of the Management and Prognosis of Pulmonary Embolism Registry. Circulation 1996;94(Suppl I):I572
  5. Hall RJ, Sutton GC, Kerr IH. Long-term prognosis of treated acute massive pulmonary embolism. Br Heart J 1977;39:1128-34 https://doi.org/10.1136/hrt.39.10.1128
  6. Kasper W, Konstantinides S, Geibel A, Tiede N, Krause T, Just H. Prognostic significance of right ventricular afterload stress detected by echocardiography in patients with clinically suspected pulmonary embolism. Heart 1997;77:346-9 https://doi.org/10.1136/hrt.77.4.346
  7. Grifoni S, Olivotto I, Cecchini P, Pieralli F, Camati A, Santoro G, et al. Short-term clinical outcome of patients with pulmonary embolism, normal blood pressure and echocardiographic right ventricular dysfunction. Circulation 2000;101:2817-22 https://doi.org/10.1161/01.CIR.101.24.2817
  8. Wan S, Quinlan DJ, Agnelli G, Eikelboom JW. Thrombolysis compared with heparin for the initial treatment of pulmonary embolism: a meta-analysis of the randomized controlled trials. Circulation 2004;110:744-9 https://doi.org/10.1161/01.CIR.0000137826.09715.9C
  9. Konstantinides S, Geibel A, Heusel G, Heinrich F, Kasper W. Heparin plus alteplase compared with heparin alone in patients with submassive pulmonary embolism. N Engl J Med 2002;347:1143-50 https://doi.org/10.1056/NEJMoa021274
  10. Harmel E, Pacouret G, Vincentelli D, Forissier JF, Peycher P, Pottier JM, et al. Thrombolysis or heparin therapy in massive pulmonary embolism with right ventricular dilation: results from a 128-patient monocenter registry. Chest 2001;120:120-5 https://doi.org/10.1378/chest.120.1.120
  11. Agnelli G, Becattini C, Kirschstein T. Thrombolysis vs heparin in the treatment of pulmonary embolism: a clinical outcome-based meta-analysis. Arch Intern Med 2002;162:2537-41 https://doi.org/10.1001/archinte.162.22.2537
  12. Kim TW, Kim WK, Zang DY, Lee JH, Kim SB, Kim SW, et al. The prevalence of Leiden(1961$G{\rightarrow}A$. mutation in the factor V gene in Korean patients suspected to have thrombosis. Korean J Thromb Hemost 1997;4: 27-31
  13. Chan LC, Bourke C, Lam CK, Liu HW, Brookes S, Pasi J, et al. Lack of activation protein C resistance in healthy Hong Kong Chinese blood donors: correlation with absence of Arg506-Gln mutation of factor V gene. Thromb Haemost 1996;75:522-3
  14. Takamiya O, Ishida F, Kodaira H, Kitano K. APCresistance and Mnl I genotype(Gln 506. coagulation factor V are rare in Japanese population. Thromb Haemost 1995;74:996
  15. Bak SM, Lee SH, Sin C, Cho JY, Shim JJ, In KH, et al. Clinical study of pulmonary thromboembolism. Tuberc Respir Dis 2001;50:106-16 https://doi.org/10.4046/trd.2001.50.1.106
  16. Alpert JS, Smith R, Carlson J, Ockene IS, Dexter L, Dalen JF. Mortality in patients treated for pulmonary embolism. JAMA 1976;236:1477-80 https://doi.org/10.1001/jama.236.13.1477
  17. Urokinase pulmonary embolism trial: phase 1 results: a cooperative study. JAMA 1970;214:2163-72 https://doi.org/10.1001/jama.214.12.2163
  18. Arcasoy SM, Kreit JW. Thrombolytic therapy of pulmonary embolism: a comprehensive review of current evidence. Chest 1999;115:1695-707 https://doi.org/10.1378/chest.115.6.1695
  19. The urokinase pulmonary embolism trial: a national cooperative study. Circulation 1973;47(Suppl 2):II1-108 https://doi.org/10.1161/01.CIR.47.1.1
  20. The PIOPED investigators. Tissue plasminogen activator for the treatment of acute pulmonary embolism. Chest 1990;97:528-33 https://doi.org/10.1378/chest.97.3.528
  21. Levine M, Hirsh J, Weitz J, Cruickshank M, Neemeh J, Gent M, et al. A randomized trial of single bolus dosage regimen of recombinant tissue plasminogen activator in patients with acute pulmonary embolism. Chest 1990;98:1473-9 https://doi.org/10.1378/chest.98.6.1473
  22. Dalla-Volta S, Palla A, Santolicandro A, Giuntini C, Pengo V, Visioli O, et al. PAIMS 2: alteplase combined with heparin versus heparin in the treatment of acute pulmonary embolism. J Am Coll Cardiol 1992;20:520-6 https://doi.org/10.1016/0735-1097(92)90002-5
  23. Geerts WH, Pineo GF, Heit JA, Bergqvit D, Lassen MR, Colwell CW, et al. Prevention of venous thromboembolism: the seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest 2004;126: 338S-400S https://doi.org/10.1378/chest.126.3_suppl.338S
  24. Yoon TR, Rowe SM, Song EK, Seon JK. Deep vein thrombosis after total hip replacement: incidence and correlation between DVT and its risk factors. J Korean Othrop Assoc 2000:35;205-10
  25. Meneveau N, Schiele F, Metz D, Valette B, Attali P, Vuillemenot A, et al. Comparative efficacy of a twohour regimen of streptokinase versus alteplase in acute massive pulmonary embolism: immediate clinical and hemodynamic outcome and one-year follow-up. J Am Coll Cardiol 1998;31:1057-63 https://doi.org/10.1016/S0735-1097(98)00068-0
  26. Chan W, Chan T. Thrombolysis for acute pulmonary embolism in Chinese patients. QJM 2000;93:125-7 https://doi.org/10.1093/qjmed/93.2.125
  27. Kasper W, Konstantinides S, Geibel A, Olschewski M, Heinrich F, Grosser KD, et al. Management strategies and determinants of outcome in acute major pulmonary embolism: results of multicenter registry. J Am Coll Cardiol 1997;30:1165-71 https://doi.org/10.1016/S0735-1097(97)00319-7